Mirtazapine Orion (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A, and blocks H1 histamine receptors. These actions together enhance noradrenergic and serotonergic neurotransmission, contributing to its antidepressant and sedative effects.

The appropriate dose of Mirtazapine Orion is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are individualized, and patients should follow the specific instructions provided by their healthcare professional.

The safety of Mirtazapine Orion in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Mirtazapine Orion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its antagonism of α2‑adrenergic, 5‑HT2, 5‑HT3 and H1 receptors. This profile often results in stronger sedative and appetite‑stimulating effects, making it useful for patients with insomnia or weight loss, whereas SSRIs typically have fewer sedative properties.

Mirtazapine Orion should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mirtazapine Orion is taken orally, usually once daily in the evening to take advantage of its sedative effect. It may be swallowed whole with or without food, unless the prescribing clinician provides alternative instructions.

Serious risks include agranulocytosis or severe neutropenia, emergence or worsening of suicidal thoughts especially early in treatment, severe allergic reactions such as Stevens‑Johnson syndrome, and hepatic dysfunction or pancreatitis. Patients should be monitored closely for any of these events and seek immediate medical attention if they occur.

Mirtazapine Orion should be avoided in individuals with known hypersensitivity to mirtazapine or any of its excipients, and in patients currently taking monoamine oxidase inhibitors (MAOIs) without an appropriate washout period. Caution is also advised for patients with severe hepatic impairment or uncontrolled epilepsy.